B Särnstrand, A H Jansson, G Matuseviciene, A Scheynius, S Pierrou, H Bergstrand
Index: J. Pharmacol. Exp. Ther. 288(3) , 1174-84, (1999)
Full Text: HTML
Oral N-acetyl-L-cysteine (NAC) is used clinically for treatment of chronic obstructive pulmonary disease. NAC is easily oxidized to its disulfide. We show here that N,N'-diacetyl-L-cystine (DiNAC) is a potent modulator of contact sensitivity (CS)/delayed type hypersensitivity (DTH) reactions in rodents. Oral treatment of BALB/c mice with 0.003 to 30 micromol/kg DiNAC leads to enhancement of a CS reaction to oxazolone; DiNAC is 100 to 1000 times more potent than NAC in this respect, indicating that it does not act as a prodrug of NAC. Structure-activity studies suggest that a stereochemically-defined disulfide element is needed for activity. The DiNAC-induced enhancement of the CS reaction is counteracted by simultaneous NAC-treatment; in contrast, the CS reaction is even more enhanced in animals treated with DiNAC together with the glutathione-depleting agent buthionine sulfoximine. These data suggest that DiNAC acts via redox processes. Immunohistochemically, ear specimens from oxazolone-sensitized and -challenged BALB/c mice treated with DiNAC display increased numbers of CD8(+) cells. DiNAC treatment augments the CS reaction also when fluorescein isothiocyanate is used as a sensitizer in BALB/c mice; this is a purported TH2 type of response. However, when dinitrofluorobenzene is used as a sensitizer, inducing a purported TH1 type of response, DiNAC treatment reduces the reaction. Treatment with DiNAC also reduces a DTH footpad-swelling reaction to methylated BSA. Collectively, these data indicate that DiNAC in vivo acts as a potent and effective immunomodulator that can either enhance or reduce the CS or DTH response depending on the experimental conditions.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
N,N'-Diacetyl-L-cystine
CAS:5545-17-5 |
C10H16N2O6S2 |
Influence of N,N'-diacetyl-L-cystine on D-galactosamine/lipo...
2004-10-01 [Yao Xue Xue Bao 39(10) , 782-6, (2004)] |
Immunomodulation with DiNAC-- a new approach to the treatmen...
2002-05-01 [Expert Opin. Investig. Drugs 11(5) , 717-20, (2002)] |
The new oral immunomodulating drug DiNAC induces brachial ar...
2008-01-01 [Atherosclerosis 196(1) , 275-82, (2008)] |
Monitoring of the subtraction process in solid-phase represe...
2001-06-27 [Gene 271(2) , 183-92, (2001)] |
[Cysteine in parenteral nutrition: comparative study of N-ac...
1988-04-01 [Infusionstherapie 15(2) , 89-92, (1988)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved